RxDoctor Payments Data

Francesca Montanari, MD

Hematology · Greenwich, CTNPI 1003134586

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $13,442 of the $13,767 with a category attached, or 97.6%. Acrotech Biopharma Inc. accounts for 61.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $11,133 and has fallen 99.2% since, to $90 in 2025.

$13,767in general payments, 2019–2025

Across 13 payments — averaging $1058.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acrotech Biopharma Inc.$8K
  • Beigene USA, Inc.$3K
  • ADC Therapeutics America, Inc.$2K
  • Pfizer$98
  • Seagen Inc.$91
  • Genmab U.S., Inc.$90
  • plus $46 from 3 others

What the payments were for

  • Consulting fees$13,44298%
  • Food & beverage$1361%
  • Education$1891%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,767 in reported general payments places this provider in the 80th percentile of 24 hematology providers in Connecticut.

See all hematology providers in Connecticut

Medicare billing

Part B allowed, 2024
$150,193
Medicare patients
411
Services billed
1,667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib41$707,848
ImbruvicaIbrutinib54$622,418
RevlimidLenalidomide33$618,973
Lenalidomide24$330,533
VenclextaVenetoclax21$306,060
TasignaNilotinib Hcl16$299,218
JaypircaPirtobrutinib11$221,855
DopteletAvatrombopag Maleate11$159,536
EliquisApixaban49$57,276
XareltoRivaroxaban15$17,414
Hydroxyurea79$1,922
Colesevelam Hcl11$1,665
Acyclovir49$1,133
Ondansetron OdtOndansetron22$524
ValacyclovirValacyclovir Hcl18$460

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Beigene USA, Inc.Brukinsa$2,625$707,84841 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$11$622,41854 claims
PfizerEliquis$98$57,27649 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 24 hematology providers in Connecticut.

Other hematology in Greenwich

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →